We are live on ! Find out more
BBP icon

Virtus Biotech ETF

14 hedge funds and large institutions have $4.32M invested in Virtus Biotech ETF in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

0% more capital invested

Capital invested by funds: $4.32M → $4.32M ($0)

7% less funds holding

Funds holding: 1514 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
14
Holders Change
-1
Holders Change %
-6.67%
% of All Funds
0.37%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
4
Reduced
3
Closed
4
Calls
Puts
Net Calls
Net Calls Change

BBP Hedge Fund Activity: Q2 2016 in Review

14 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q2 2016, worth a combined $4.32M — unchanged from a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of BBP and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 4 added.

The largest buyer was Royal Bank of Canada, adding an estimated $913K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $561K sold.

  • 14 institutional investors held Virtus Biotech ETF (BBP) as of Q2 2016, down from 15 in Q1 2016.
  • Funds reported $4.32M of Virtus Biotech ETF stock for Q2 2016, unchanged quarter-over-quarter.
  • 3 funds opened new Virtus Biotech ETF positions in Q2 2016 and 4 closed out, a net change of -1 holder.
  • The largest Virtus Biotech ETF buyer in Q2 2016 was Royal Bank of Canada, an estimated $913K added.
  • The largest Virtus Biotech ETF seller in Q2 2016 was Virtu KCG Holdings, an estimated $561K sold.

Based on aggregated 13F filings for Q2 2016.